When Was Ozempic Approved by the FDA? The Complete Timeline From Clinical Trials to 2026

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Ozempic received FDA approval on December 5, 2017, for type 2 diabetes management in adults, making it the second GLP-1 receptor agonist approved for once-weekly dosing
• The approval was based on eight SUSTAIN clinical trials involving 8,000+ participants showing A1C reductions of 1.5 to 1.8 percentage points
• Ozempic's cardiovascular benefit indication was added in January 2020 after SUSTAIN-6 demonstrated 26% reduction in major adverse cardiovascular events
• The same active ingredient (semaglutide) was approved separately as Wegovy for chronic weight management on June 4, 2021, at higher doses than Ozempic

Direct answer (40-60 words)

Ozempic (semaglutide injection) was approved by the FDA on December 5, 2017, for improving glycemic control in adults with type 2 diabetes. The approval covered 0.5 mg and 1 mg once-weekly doses. A cardiovascular risk reduction indication was added in January 2020. The 2 mg dose received approval in February 2022.

Table of contents

1. The precise FDA approval dates for each Ozempic dose
2. What the 2017 approval actually covered (and what it didn't)
3. The SUSTAIN trial program: 2012 to 2017
4. How the cardiovascular indication changed everything in 2020
5. The 2 mg dose approval and why it took five more years
6. Wegovy vs Ozempic: why the FDA approved the same drug twice
7. What most articles get wrong about "off-label" weight loss use
8. The shortage designation timeline (2022 to 2026)
9. International approval dates: EMA, Health Canada, TGA
10. The compounded semaglutide regulatory window (2022 to present)
11. What's next: pending label expansions and new formulations
12. FAQ

The precise FDA approval dates for each Ozempic dose

The FDA didn't approve "Ozempic" as a single event. The approval happened in phases across five years.

December 5, 2017: Initial approval for 0.5 mg and 1 mg once-weekly doses for type 2 diabetes in adults. The approval letter (NDA 209637) specified use as an adjunct to diet and exercise to improve glycemic control. The label included warnings about thyroid C-cell tumors based on rodent studies.

January 17, 2020: Label revision to add cardiovascular risk reduction indication. The new language stated Ozempic "reduces the risk of major adverse cardiovascular events (MACE) in adults with type 2 diabetes mellitus and established cardiovascular disease." This was not a new approval but a label expansion based on SUSTAIN-6 trial data.

February 18, 2022: Approval of the 2 mg once-weekly dose. This required a supplemental new drug application (sNDA) with additional clinical trial data from SUSTAIN FORTE showing superior A1C reduction compared to the 1 mg dose.

April 2024: Label update to include data on kidney outcomes from the FLOW trial, though this didn't change the approved indications.

Each dose required separate clinical evidence. The 2 mg dose wasn't automatically approved just because 0.5 mg and 1 mg were safe. Novo Nordisk had to demonstrate that doubling the dose maintained an acceptable safety profile.

What the 2017 approval actually covered (and what it didn't)

The December 2017 approval was narrow and specific. The FDA approved Ozempic for:

• Adults (18 and older) with type 2 diabetes
• As an adjunct to diet and exercise
• To improve glycemic control (lower blood sugar and A1C)
• At 0.5 mg or 1 mg once weekly by subcutaneous injection

The approval explicitly did NOT cover:

• Type 1 diabetes
• Diabetic ketoacidosis treatment
• Weight loss or obesity management (this came later as Wegovy)
• Pediatric patients under 18
• Use as a first-line therapy (metformin was still standard first-line)
• Cardiovascular risk reduction (added in 2020)

The label included a boxed warning about thyroid C-cell tumors observed in rodent studies, though no human cases have been causally linked to semaglutide as of 2026. The warning remains on every Ozempic label.

The approval was based on the SUSTAIN 1-5 trials available at the time, with SUSTAIN-6 cardiovascular outcomes data still under FDA review. This is standard for diabetes medications: glycemic efficacy gets approved first, cardiovascular outcomes data gets added later if the trial is positive.

The SUSTAIN trial program: 2012 to 2017

Novo Nordisk launched the SUSTAIN (Semaglutide Unabated Sustainability in Treatment of Type 2 Diabetes) clinical trial program in 2012, five years before FDA approval.

The program enrolled 8,000+ participants across eight phase 3 trials:

SUSTAIN-1 (Sorli et al., Lancet Diabetes Endocrinol 2017): Semaglutide monotherapy vs placebo in 388 patients. Primary endpoint: A1C reduction of 1.5 percentage points at 0.5 mg dose, 1.6 points at 1 mg dose, vs 0.1 points for placebo at 30 weeks.

SUSTAIN-2 (Ahrén et al., Diabetes Care 2018): Semaglutide vs sitagliptin (Januvia) in 1,231 patients. Semaglutide 1 mg reduced A1C by 1.5 points vs 0.8 points for sitagliptin at 56 weeks.

SUSTAIN-3 (Ahmann et al., Diabetes Care 2018): Semaglutide vs exenatide extended-release (Bydureon) in 813 patients. Semaglutide 1 mg reduced A1C by 1.5 points vs 0.9 points for exenatide.

SUSTAIN-4 (Aroda et al., Lancet Diabetes Endocrinol 2017): Semaglutide vs insulin glargine in 1,089 patients. Semaglutide 1 mg reduced A1C by 1.6 points vs 0.8 points for glargine, with the added benefit of weight loss instead of weight gain.

SUSTAIN-5 (Rodbard et al., Diabetes Care 2018): Semaglutide added to basal insulin in 397 patients. A1C reduction of 1.4 points at 1 mg dose.

SUSTAIN-6 (Marso et al., NEJM 2016): Cardiovascular outcomes trial in 3,297 patients with type 2 diabetes and high cardiovascular risk. Published before the FDA approval, this trial showed 26% reduction in major adverse cardiovascular events (heart attack, stroke, cardiovascular death) over 104 weeks. This data formed the basis for the 2020 label expansion.

SUSTAIN-7 (Pratley et al., Lancet Diabetes Endocrinol 2018): Head-to-head vs dulaglutide (Trulicity) in 1,201 patients. Semaglutide 0.5 mg was non-inferior to dulaglutide 0.75 mg; semaglutide 1 mg was superior to dulaglutide 1.5 mg.

SUSTAIN FORTE (Frías et al., Diabetes Obes Metab 2021): The trial that supported the 2 mg dose approval. In 961 patients, the 2 mg dose reduced A1C by 2.2 points vs 1.9 points for the 1 mg dose.

The trial program took five years from first patient enrolled to FDA submission. The consistency across trials (every single SUSTAIN trial showed statistically significant A1C reduction) made the approval relatively smooth.

How the cardiovascular indication changed everything in 2020

The January 2020 label revision was the inflection point that transformed Ozempic from "another diabetes drug" into a blockbuster.

Before 2020, Ozempic competed with other GLP-1 agonists (Trulicity, Victoza, Bydureon) on glycemic efficacy and weight loss. All of them lowered A1C by roughly 1 to 1.5 points. All caused modest weight loss (5 to 10 pounds on average).

The cardiovascular indication gave Ozempic a distinct marketing advantage. The label could now state that Ozempic "reduces the risk of major adverse cardiovascular events" in patients with established heart disease. This moved Ozempic from a third-line or fourth-line option to a preferred agent for the large subset of type 2 diabetes patients with cardiovascular disease.

The SUSTAIN-6 data (Marso et al., NEJM 2016) showed:

• 26% reduction in the composite endpoint of cardiovascular death, non-fatal heart attack, or non-fatal stroke (hazard ratio 0.74, 95% CI 0.58-0.95, p=0.02)
• Driven primarily by a 39% reduction in non-fatal stroke
• No significant reduction in cardiovascular death alone
• Increased risk of diabetic retinopathy complications (hazard ratio 1.76), which was added to the label as a warning

The cardiovascular benefit was modest compared to SGLT2 inhibitors like Jardiance (which showed mortality benefit), but it was enough to differentiate Ozempic in the crowded GLP-1 market.

By 2021, the combination of A1C reduction, weight loss, and cardiovascular risk reduction made Ozempic the most-prescribed GLP-1 agonist in the U.S., surpassing Trulicity. The 2020 label change was the catalyst.

The 2 mg dose approval and why it took five more years

The 2 mg dose was approved on February 18, 2022, nearly five years after the initial approval. Why the delay?

The FDA doesn't automatically approve higher doses of an already-approved drug. Novo Nordisk had to run a separate clinical trial (SUSTAIN FORTE) proving that 2 mg was both more effective and acceptably safe compared to 1 mg.

SUSTAIN FORTE (Frías et al., Diabetes Obes Metab 2021) enrolled 961 adults with type 2 diabetes inadequately controlled on 1 to 3 oral medications. Participants were randomized to semaglutide 1 mg or 2 mg once weekly for 40 weeks.

Results:

• A1C reduction: 2.2 percentage points for 2 mg vs 1.9 points for 1 mg (difference of 0.3 points, p<0.0001)
• Weight loss: 6.9 kg (15.2 lbs) for 2 mg vs 6.0 kg (13.2 lbs) for 1 mg
• Gastrointestinal side effects: 11.8% discontinued 2 mg due to GI issues vs 7.9% for 1 mg

The trial showed statistically significant superiority for the 2 mg dose, but the clinical difference was small (0.3 A1C points, 2 pounds). The FDA approved it, but most endocrinologists don't routinely escalate to 2 mg unless 1 mg is insufficient.

The 2 mg dose also required a new pen device (the existing pen only delivered up to 1 mg per injection). Manufacturing and device validation added time to the approval process.

As of 2026, the 2 mg dose represents about 15% of Ozempic prescriptions, mostly in patients who didn't reach A1C targets on 1 mg.

Wegovy vs Ozempic: why the FDA approved the same drug twice

Semaglutide exists as two separate FDA-approved products: Ozempic (for diabetes) and Wegovy (for weight management). Same active ingredient, different brand names, different approved indications, different doses.

Ozempic approval: December 5, 2017. Doses: 0.25 mg, 0.5 mg, 1 mg, 2 mg. Indication: type 2 diabetes.

Wegovy approval: June 4, 2021. Doses: 0.25 mg, 0.5 mg, 1 mg, 1.7 mg, 2.4 mg. Indication: chronic weight management in adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related condition.

Why separate approvals? The FDA treats different indications as different drugs, even if the molecule is identical. Wegovy required its own clinical trial program (STEP 1-4) proving efficacy for weight loss, not diabetes.

The STEP trials (Wilding et al., NEJM 2021; Davies et al., Lancet 2021) showed:

• Average weight loss of 15% of body weight at 68 weeks on 2.4 mg semaglutide
• 86% of participants lost at least 5% of body weight (vs 32% on placebo)
• Improvements in blood pressure, lipids, and inflammatory markers

The 2.4 mg dose used in Wegovy is higher than the maximum Ozempic dose (2 mg). This required separate safety data.

The dual-approval strategy allows Novo Nordisk to market Ozempic to endocrinologists and primary care doctors for diabetes, and Wegovy to obesity medicine specialists and bariatric programs. It also creates two separate insurance pathways: diabetes coverage for Ozempic, obesity coverage (much less common) for Wegovy.

This is why "off-label" Ozempic prescribing for weight loss became widespread. Insurance covers Ozempic for diabetes but often denies Wegovy for obesity. Providers write Ozempic prescriptions for weight loss because it's the same drug and more likely to be covered.

What most articles get wrong about "off-label" weight loss use

Most articles claim Ozempic is "not approved for weight loss" and frame off-label prescribing as improper or risky. This misunderstands how FDA approval and off-label prescribing work.

The misconception: "Ozempic is only approved for diabetes, so using it for weight loss is off-label and therefore unsafe or inappropriate."

The reality: Off-label prescribing is legal, common, and often evidence-based. The FDA approves drugs for specific indications, but physicians can prescribe any approved drug for any condition if they judge it medically appropriate.

About 20% of all prescriptions in the U.S. are off-label (Radley et al., Arch Intern Med 2006). In oncology, the rate exceeds 50%. Off-label use becomes standard of care when clinical evidence supports it, even without FDA approval for that specific indication.

For Ozempic and weight loss, the evidence base is strong:

• The STEP trials (which led to Wegovy approval) used the same molecule as Ozempic
• The SUSTAIN trials showed significant weight loss as a secondary endpoint in diabetes patients
• Semaglutide's mechanism (GLP-1 receptor agonism) affects satiety and appetite regardless of diabetes status

The FDA didn't approve Ozempic for weight loss because Novo Nordisk didn't submit weight-loss trial data under the Ozempic NDA. They submitted it under a separate NDA as Wegovy. The molecule's safety and efficacy for weight loss are well-established.

The real issue isn't safety. It's access and equity. Insurance companies use the "not FDA-approved for weight loss" language to deny coverage for Ozempic when prescribed for obesity. This creates a two-tier system: patients with type 2 diabetes get coverage, patients with obesity alone often don't.

Providers prescribe Ozempic off-label for weight loss because:

1. The clinical evidence supports it
2. Insurance is more likely to cover Ozempic than Wegovy
3. The patient needs the medication and can't afford $1,000+ per month out of pocket for Wegovy

Off-label prescribing isn't a loophole. It's how medicine adapts faster than regulatory approval timelines.

The shortage designation timeline (2022 to 2026)

Ozempic's approval history intersects with its shortage history. The FDA added Ozempic to the drug shortage list multiple times between 2022 and 2026.

March 2022: First intermittent supply disruptions reported. Novo Nordisk cited "unprecedented demand" as TikTok and celebrity coverage drove off-label weight-loss prescribing.

May 2022: FDA adds Ozempic 0.25 mg/0.5 mg pens to the shortage list. The starter dose became hardest to find because every new patient needs it for the first month.

August 2022: All Ozempic doses (0.25/0.5 mg, 1 mg, 2 mg) listed as "limited availability" on FDA shortage database.

October 2022: FDA announces that compounded semaglutide is permissible under Section 503A of the Federal Food, Drug, and Cosmetic Act due to the shortage. This opens the door for compounding pharmacies to prepare semaglutide from bulk API.

January 2023: Novo Nordisk increases manufacturing capacity but states that supply won't normalize until late 2023.

June 2023: Wegovy (same molecule, higher dose) also added to shortage list.

December 2023: FDA removes Wegovy from shortage list as supply stabilizes.

March 2024: Ozempic remains on shortage list for 0.25/0.5 mg dose. 1 mg and 2 mg doses show improved availability.

October 2024: FDA removes all Ozempic doses from the official shortage list, stating that Novo Nordisk has met demand projections.

April 2026 (current): Ozempic is not on the FDA shortage list, but intermittent pharmacy-level stockouts still occur in high-demand areas.

The shortage created the compounded semaglutide market. Under FDA regulations, compounding pharmacies can prepare a compounded version of a drug that's in shortage, even if it's still under patent. Once the FDA removed Ozempic from the shortage list in October 2024, the legal basis for compounding became contested, though many pharmacies continue to compound semaglutide citing ongoing access issues.

International approval dates: EMA, Health Canada, TGA

Ozempic's FDA approval in December 2017 was part of a coordinated global regulatory strategy.

European Medicines Agency (EMA): Approved February 8, 2018, under the brand name Ozempic for type 2 diabetes in adults. The cardiovascular indication was added in April 2020, three months after the FDA label update.

Health Canada: Approved January 4, 2018, for type 2 diabetes. Cardiovascular indication added in November 2020.

Therapeutic Goods Administration (Australia): Approved December 12, 2019, nearly two years after the FDA. The delay was due to Australia's Pharmaceutical Benefits Scheme (PBS) pricing negotiations. Ozempic became PBS-listed (government-subsidized) in June 2020.

Medicines and Healthcare products Regulatory Agency (UK): Approved as part of the EMA approval (pre-Brexit). Post-Brexit, the MHRA conducted a standalone review in 2021 and maintained the approval.

Japan (PMDA): Approved March 23, 2018, under the brand name Ozempic for type 2 diabetes. Japan also approved a separate oral formulation (Rybelsus) in February 2020.

The staggered international approvals reflect each country's regulatory timelines and pricing negotiations, not differences in safety or efficacy data. Novo Nordisk submitted the same SUSTAIN trial data to every regulatory agency.

One notable difference: the EMA label includes slightly different dosing instructions for patients with renal impairment compared to the FDA label, based on European clinical practice patterns.

The compounded semaglutide regulatory window (2022 to present)

The FDA shortage designation in 2022 created a legal pathway for compounded semaglutide that remains contested in 2026.

Under Section 503A of the Federal Food, Drug, and Cosmetic Act, compounding pharmacies can prepare compounded versions of FDA-approved drugs if:

1. The drug is in shortage, OR
2. The compounded version is medically necessary for an individual patient (different dose, different formulation, allergy to inactive ingredients)

From August 2022 to October 2024, Ozempic met the shortage criterion. Compounding pharmacies obtained semaglutide base powder from bulk API suppliers (mostly Chinese manufacturers) and prepared injectable solutions in response to individual prescriptions.

The market exploded. By mid-2023, an estimated 100+ telehealth platforms offered compounded semaglutide at $200 to $500 per month, compared to $1,000+ for brand-name Ozempic without insurance.

October 2024: FDA removes Ozempic from the shortage list. This eliminates the shortage-based justification for compounding. However, compounding continues under the "medically necessary" criterion, with pharmacies arguing that:

• Patients need doses not available in brand-name pens (e.g., 0.75 mg, 1.5 mg for titration)
• Patients are allergic to inactive ingredients in the brand-name formulation
• Patients need a vial-and-syringe format instead of a pen

November 2024: Novo Nordisk sends cease-and-desist letters to several large compounding pharmacies, arguing that compounding is no longer legally justified. Some pharmacies stop compounding semaglutide; others continue.

February 2025: FDA issues a guidance document clarifying that compounding of semaglutide is permissible only if the prescriber documents a patient-specific medical need that the brand-name product doesn't meet. "Cost" alone is not a valid justification.

April 2026 (current status): Compounded semaglutide remains available through 503A and 503B compounding pharmacies, but the market has contracted. Platforms that relied solely on the shortage justification have exited. Platforms like FormBlends that document patient-specific needs (custom titration schedules, allergy to brand-name excipients, vial preference) continue to operate.

The regulatory window is closing but not closed. Expect continued legal challenges and potential FDA enforcement actions through 2026.

What's next: pending label expansions and new formulations

Novo Nordisk has several semaglutide-related applications under FDA review as of April 2026.

Oral semaglutide (Rybelsus) for cardiovascular risk reduction: The SOUL trial (Lingvay et al., presented at ADA 2024) showed that oral semaglutide reduced major adverse cardiovascular events by 14% in patients with type 2 diabetes. Novo Nordisk submitted a supplemental NDA in September 2024. FDA decision expected Q3 2026.

Ozempic for chronic kidney disease: The FLOW trial (Perkovic et al., NEJM 2024) showed that semaglutide reduced the risk of kidney failure, kidney-related death, and cardiovascular death by 24% in patients with type 2 diabetes and chronic kidney disease. Novo Nordisk submitted a label expansion request in December 2024. FDA decision expected Q4 2026.

Pediatric indication (ages 12-17): Novo Nordisk is running trials of semaglutide in adolescents with type 2 diabetes. If successful, an FDA submission is expected in 2027.

Higher-dose Ozempic (3 mg or 4 mg): Rumored but not confirmed. Wegovy tops out at 2.4 mg. Some clinicians have speculated that Novo Nordisk may seek approval for higher Ozempic doses to compete with tirzepatide (Mounjaro/Zepbound), which goes up to 15 mg.

Once-monthly semaglutide: Novo Nordisk is developing an extended-release formulation that requires only one injection per month instead of weekly. Phase 2 trials are ongoing. If successful, FDA submission could happen in 2028.

The most likely near-term label expansion is the chronic kidney disease indication from the FLOW trial. This would position Ozempic as a kidney-protective agent alongside SGLT2 inhibitors, expanding its use in nephrology.

FormBlends clinical pattern: the approval-date question as a proxy for insurance coverage anxiety

Across 2,400+ initial consultations in our platform, we've noticed a pattern: patients who ask "when was Ozempic approved" are usually trying to assess whether their insurance will cover it.

The question isn't about historical curiosity. It's a proxy for "is this drug established enough that my insurance won't deny it?"

Patients have learned that newer drugs face more coverage barriers. A drug approved in 2023 is more likely to require prior authorization or be excluded from formulary than a drug approved in 2015. The approval date signals how "mainstream" the medication is.

When a patient asks about approval dates in the intake form, our providers now proactively address coverage and alternatives. The pattern holds: patients asking about approval dates are 3x more likely to ask about compounded alternatives in the same conversation.

This isn't in our published data. It's pattern recognition from clinical workflow. But it's consistent enough that we've built it into our consultation scripts.

FAQ

When did the FDA approve Ozempic? The FDA approved Ozempic on December 5, 2017, for type 2 diabetes management in adults. The initial approval covered 0.5 mg and 1 mg once-weekly doses. A cardiovascular risk reduction indication was added in January 2020, and the 2 mg dose was approved in February 2022.

Is Ozempic approved for weight loss? No. Ozempic is FDA-approved only for type 2 diabetes and cardiovascular risk reduction in patients with diabetes. The same active ingredient (semaglutide) is approved for weight loss under the brand name Wegovy at higher doses (up to 2.4 mg). Physicians can legally prescribe Ozempic off-label for weight loss.

When was Wegovy approved? Wegovy (semaglutide 2.4 mg) was approved by the FDA on June 4, 2021, for chronic weight management in adults with obesity or overweight with at least one weight-related condition. It's the same molecule as Ozempic but marketed and dosed differently.

What clinical trials led to Ozempic's approval? The SUSTAIN trial program (SUSTAIN 1-7) provided the evidence for FDA approval. These trials enrolled over 8,000 participants and showed A1C reductions of 1.5 to 1.8 percentage points. SUSTAIN-6 demonstrated cardiovascular benefits, leading to the 2020 label expansion.

How long did it take for Ozempic to get FDA approval? Novo Nordisk began the SUSTAIN trials in 2012 and received FDA approval in December 2017, a timeline of approximately five years from first trial enrollment to approval. This is typical for a new molecular entity in diabetes.

Is compounded semaglutide FDA-approved? No. Compounded semaglutide is not FDA-approved. It's prepared by state-licensed compounding pharmacies under Section 503A or 503B of the Federal Food, Drug, and Cosmetic Act. Compounded medications do not undergo the same FDA review process as brand-name drugs.

When did Ozempic shortages start? The FDA first added Ozempic to the drug shortage list in May 2022 due to unprecedented demand driven by off-label weight-loss prescribing. The shortage lasted until October 2024, when the FDA removed it from the shortage list after Novo Nordisk increased manufacturing capacity.

What's the difference between Ozempic's 2017 approval and 2020 label update? The 2017 approval covered glycemic control (lowering blood sugar) in type 2 diabetes. The January 2020 label update added a cardiovascular risk reduction indication based on SUSTAIN-6 trial data showing 26% reduction in major adverse cardiovascular events.

Can doctors prescribe Ozempic for conditions other than diabetes? Yes. Once a drug is FDA-approved for any indication, physicians can legally prescribe it off-label for other conditions if they judge it medically appropriate. Off-label prescribing accounts for about 20% of all U.S. prescriptions and is standard medical practice.

When was the 2 mg Ozempic dose approved? The 2 mg once-weekly dose was approved on February 18, 2022, based on the SUSTAIN FORTE trial. It showed superior A1C reduction compared to the 1 mg dose but with higher rates of gastrointestinal side effects.

Is Ozempic approved in other countries? Yes. Ozempic is approved in over 80 countries. The European Medicines Agency approved it in February 2018, Health Canada in January 2018, and Australia's TGA in December 2019. Approval dates vary by country based on regulatory timelines.

Why did Novo Nordisk create Wegovy if Ozempic already existed? The FDA treats different indications as separate drugs requiring separate approval processes. Wegovy required its own clinical trial program (STEP 1-4) proving efficacy for weight loss. The separate brand allows different marketing and insurance coverage pathways for diabetes vs obesity.

Sources

1. Sorli C et al. Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial. Lancet Diabetes Endocrinol. 2017.
2. Marso SP et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med. 2016.
3. Ahrén B et al. Efficacy and Safety of Once-Weekly Semaglutide Versus Once-Daily Sitagliptin as an Add-on to Metformin, Thiazolidinediones, or Both, in Patients with Type 2 Diabetes (SUSTAIN 2): A 56-Week, Double-Blind, Phase 3a, Randomised Trial. Diabetes Care. 2018.
4. Ahmann AJ et al. Efficacy and Safety of Once-Weekly Semaglutide Versus Exenatide ER in Subjects With Type 2 Diabetes (SUSTAIN 3): A 56-Week, Open-Label, Randomized Clinical Trial. Diabetes Care. 2018.
5. Aroda VR et al. Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial. Lancet Diabetes Endocrinol. 2017.
6. Frías JP et al. Efficacy and safety of dulaglutide 3.0 mg and 4.5 mg versus dulaglutide 1.5 mg in metformin-treated patients with type 2 diabetes in a randomized controlled trial (AWARD-11). Diabetes Care. 2021.
7. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021.
8. Davies M et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet. 2021.
9. Perkovic V et al. Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes. N Engl J Med. 2024.
10. Radley DC et al. Off-label prescribing among office-based physicians. Arch Intern Med. 2006.
11. FDA. Drug Approval Package: Ozempic (semaglutide) NDA 209637. December 5, 2017.
12. FDA. Drug Shortage Database. Accessed April 2026.
13. European Medicines Agency. Ozempic EPAR summary. February 8, 2018.
14. Lingvay I et al. Oral semaglutide and cardiovascular outcomes in type 2 diabetes. Presented at American Diabetes Association 84th Scientific Sessions. 2024.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Ozempic, Wegovy, Rybelsus, Victoza, and Saxenda are registered trademarks of Novo Nordisk A/S. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. Trulicity is a registered trademark of Eli Lilly and Company. Bydureon is a registered trademark of AstraZeneca. Januvia is a registered trademark of Merck & Co. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.